U.S. markets closed

Gracell Biotechnologies Inc. (GRCL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
13.31-0.12 (-0.89%)
At close: 4:00PM EDT
14.34 +1.03 (7.74%)
After hours: 05:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close13.43
Open13.46
Bid12.80 x 1000
Ask14.35 x 1400
Day's Range13.16 - 14.35
52 Week Range9.75 - 33.70
Volume199,285
Avg. Volume126,981
Market Cap894.608M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMay 17, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est34.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Gracell Biotechnologies Reschedules Clinical Update Conference Call and Webcast to June 14, 2021
    GlobeNewswire

    Gracell Biotechnologies Reschedules Clinical Update Conference Call and Webcast to June 14, 2021

    SUZHOU, China and PALO ALTO, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it has rescheduled its conference call and webcast to present an update on the results of a Phase 1 first-in-human multicenter investigator-initiated study of the FasTCAR-enabled BCMA

  • Gracell Biotechnologies Hosting Key Opinion Leader Webinar on High Risk Multiple Myeloma, Treatment Challenges and Dual-Targeting CAR-T with Overnight Manufacturing - a Novel Approach for Treatment of Multiple Myeloma
    PR Newswire

    Gracell Biotechnologies Hosting Key Opinion Leader Webinar on High Risk Multiple Myeloma, Treatment Challenges and Dual-Targeting CAR-T with Overnight Manufacturing - a Novel Approach for Treatment of Multiple Myeloma

    Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will host a key opinion leader (KOL) webinar on the challenges of treating High Risk Multiple Myeloma and a potential novel approach on Friday, June 11, 2021 at 8:00am Eastern Time.

  • Gracell Biotechnologies to Participate in Upcoming Virtual Conferences in June
    GlobeNewswire

    Gracell Biotechnologies to Participate in Upcoming Virtual Conferences in June

    SUZHOU, China and PALO ALTO, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will participate in the following upcoming virtual conferences: Jefferies Virtual Healthcare ConferenceOne-on-one and small group meetings: June 1-4, 2021Fireside chat: June 4, 2021, 8:00 – 8:25 am ETWebcast link: https://ir.gracellbio.com/news-events/events-and-presentationsThe replay of the fireside chat can be accessed through the “News and Events” section of the Gracell Investor website.For more information, please contact your Jefferies representative. Citi Pan-Asia Regional Investor ConferenceOne-on-one and small group meetings: June 2-4, 2021For more information, please contact your Citi representative. About GracellGracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit www.gracellbio.comFollow @GracellBio on LinkedIn Media contactMarvin Tangmarvin.tang@gracellbio.com Investor contactGracie Tonggracie.tong@gracellbio.com